参考文献/References:
[1] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].Ca A Cancer Journal for Clinicians,2016,66(2):115-132.[2] Siegel R L,Miller K D,Fedewa S A,et al.Colorectal cancerstatistics,2017[J].Ca A Cancer Journal for Clinicians,2017,67(3):104,17.[3] Semenova EA,Nagel R,Berns A.Origins,genetic landscape,and emerging therapies of small cell lung cancer[J].Genes&Development,2015,29(14):1447,62.[4] Kalemkerian G P,Wallace A, Downey R J,et al.Small celllung cancer[J].Journal of the National ComprehensiveCancer Network,2008,6(3):294-314.[5] Hicklin D J,Ellis L M.Role of the vascular endothelialgrowth factor pathway in tumor growth and angiogenesis[J].Journal of Clinical Oncology,2005,23(5):1011-1027.[6] Pujol J L,Breton J L,Gervais R,et al.Phase III doubleblind,placebo-controlled study of thalidomide in extensivediseasesmall-cell lung cancer after response to chemotherapy:an intergroup study FNCLCC cleo04 IFCT 00-01[J].Journalof Clinical Oncology,2007,25(25):3945- 3951.[7] Dowlati A,Subbiah S,Cooney M,et al.Phase II trial ofthalidomide as maintenance therapy for extensive stagesmall cell lung cancer after response to chemotherapy.[J].Lung Cancer,2007,56(3):377-381.[8] Lee SM,Woll PJ,Rudd R,et al.Antiangiogenictherapyusing thalidomide combined with chemotherapy in smallcell lung cancer:a randomized,double-blind,placebo- controlledtrial[J].Jnci Journal of the National Cancer Institute,2009,101(15):1049,57.[9] Tiseo M,Boni L,Ambrosio F,et al.Italian,multicenter,phaseⅢ,randomized study of cisplatin plus etoposide with orwithout bevacizumab as first line treatment in extensivedisease small cell lung cancer:The GOIRC AIFAFARM6PMFJM Trial[J].Journal of Clinical Oncology,2017,35(12):1281-1287.[10] Pujol JL,Lavole A,Quoix E,et al. Randomized phase Ⅱ-Ⅲstudy of bevacizumab in combination with chemotherapy inpreviously untreated extensive small-cell lung cancer:results from the IFCT-0802 Trial[J].Annals of Oncology,2015,26(5):908,14.[11] Spigel DR,Townley PM,Waterhouse DM,et al. Randomizedphase Ⅱ study of bevacizumab in combination withchemotherapy in previously untreated extensive-stagesmall-cell lung cancer:results from the SALUTE trial[J].Journal of Clinical Oncology,2011,29(16):2215-2222.[12] Ready NE,Dudek AZ,Pang HH,et al.Cisplatin,irinotecan,and bevacizumab for untreated extensive-stage small-celllung cancer:CALGB 30306,a phase Ⅱ study[J].Journal ofClinical Oncology,2011,29(33):4436-4441.[13] Petrioli R,Roviello G,Laera L,et al.Cisplatin, etoposide, andbevacizumab regimen followed by oral etoposide andbevacizumab maintenance treatment in patients withextensive-tage small cell lung cancer:a single-institutionexperience[J].Clinical Lung Cancer,2015,6(6):e229-e234.